Navigation Links
The Hemostemix Group of Companies Provides Corporate Strategy Update
Date:5/31/2013

Toronto, Ontario (PRWEB) May 31, 2013

The Hemostemix Group of Companies released an update today available to shareholders and potential investors outlining key elements of its strategic plan for the upcoming year.

The Hemostemix Group is comprised of HemoStemix Ltd. (HemoStemix), a company incorporated in Israel with an operating research, development and manufacturing facility in Ness Ziona, Kwalata Trading Ltd. (“Kwalata”), registered in Cyprus, and the parent company Theravitae, Inc. (“TVI”) based in Toronto, Ontario, Canada (collectively the “Hemostemix Group” or “Group”).

Corporate

On May 14, Technical Ventures RX Corp. (TSX-V:TIK.P) announced a letter of intent signed with TVI regarding a proposed Qualifying Transaction in which TIK.P would acquire TVI in a share exchange. For a copy of the press release, see http://bit.ly/TVI-TIK.

Financing

TVI has also announced that it has engaged Wolverton Securities Ltd. as agent for a private placement, on a commercially reasonable efforts basis, for minimum gross proceeds of $1 million.

Funding

The Hemostemix Group has identified several sources of non-dilutive grant or match funding that it intends to pursue in the near-term for projects which are critical to expediting the company’s commercialization strategy.

Clinical Trial

The Group has completed three clinical trials to-date, the data from which were submitted last year to Health Canada and which formed the basis for its recent clearance to proceed with a phase 2 clinical trial in Canada for the treatment of critical limb ischemia. That trial is expected to start later this year.

Research & Development

Recently the Group also announced that a Letter of Intent has been signed with the Austrian-based Ludwig Boltzmann Institute for Experimental and Clinical Traumatology (“LBI”) to collaborate in performing experiments to assess various clinical applications for Hemostemix’ technology as well as other potential mutually beneficial projects. The LBI is an organization dedicated to research in the fields of tissue engineering, stem cells and regenerative medicine For more information on LBI, see http://trauma.lbg.ac.at/en/about-us.

Commercial

The company continues to aggressively file and maintain a global patent portfolio covering a broad technology platform now protected by 37 patents issued in major markets. The Hemostemix Group is also actively identifying and engaging in early-stage discussions pertaining to potential commercial licenses, joint-ventures, and other types of strategic collaborations.

About HemoStemix Ltd.

HemoStemix Ltd. is a company incorporated in Israel with an operating research, development and manufacturing facility in Kiryat Weizmann Science Park, Ness Ziona. HemoStemix and Kwalata Trading Ltd. (“Kwalata”), registered in Cyprus, are wholly-owned subsidiaries of Canadian-based parent company TVI (together the “Hemostemix Group”). Kwalata holds the intellectual property on behalf of the Hemostemix Group.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10777802.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Eurofins MWG Operon Quality Assurance Group Completes ISO Certifications for Their New Overnight Sequencing Lab
2. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
3. Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group
4. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
5. MZ Group to Sponsor Asia BiotechInvest 2013 Conference
6. DTx Partners with Caxiam Group for DTx.com Redesign
7. Jackson Hole Group, LLC Welcomes Marnie McBryde as a New Principal
8. PAREXEL International Announces Acquisition of HERON Group LTD, A Leading Commercialization Consultancy
9. Cellular Biomedicine Group Provides Update and 2013 Milestones
10. Oncotest GmbH and Debiopharm Group Announce a Successful Partnership in the Identification of Biomarker Candidates
11. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2019)... ... August 08, 2019 , ... Inference ... and service organizations, today announced that the company’s Studio Intelligent Virtual Agent (IVA) ... market . Inference will officially accept the award at Frost & Sullivan’s annual ...
(Date:8/6/2019)... ... August 06, 2019 , ... The ... the launch of a community project that will engage middle and early high ... project, entitled “A Youth-Led Citizen Science Network for Community Environmental Assessment.” Collaborative partners ...
(Date:7/19/2019)... ... 18, 2019 , ... Global precision motion and piezo technology ... motion facilities in Lederhose, Germany, increasing their current footprint by half again. , ... in addition to general office space, a significant increase to its existing 129,000ft² ...
(Date:7/11/2019)... ... July 11, 2019 , ... At the most recent ... regenerative therapies to eight military Veterans under the R3 Heroes Program. The Veterans included ... The R3 Heroes Program allow anyone to nominate a military Veteran, teacher or first ...
Breaking Biology Technology:
(Date:8/6/2019)... ... August 06, 2019 , ... The demand for plant-based ... in particular quickly entered the limelight – meat alternatives. Yet, to make these ... emulsifying ingredient such as methyl cellulose. This ingredient is highly synthetic. Having a ...
(Date:8/1/2019)... CAMBRIDGE, Mass. (PRWEB) , ... August 01, 2019 , ... ... announced by Johannes Fruehauf, MD, PhD, founder and president of BioLabs, which provides premier ... created the CFO role to strengthen our ability to forecast and manage growth,” says ...
(Date:8/1/2019)... ... 2019 , ... USDM Life Sciences (USDM) announces that Jay Crowley, Vice President ... addressing challenges with the upcoming EU MDR IVDR regulations . , ... variety of positions over his 26 years at the FDA, including developing the framework ...
Breaking Biology News(10 mins):